Clinical trials: ITP, open to volunteers
ITP - Immune Thrombocytopenia
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and…
- Trial name
- Ava dosing (NCT07133659)
- Testing
- Avatrombopag 20 mg Oral Tablet
- Where
- Iraq
- Volunteers
- 25 people
- Sponsor
- Al-Mustansiriyah University
Immune Thrombocytopenia (ITP), ITP
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
- Conditions
- Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal
- Trial name
- NCT07043946
- Testing
- Budoprutug
- Where
- 20 sites in Bulgaria, Greece and 3 more
- Volunteers
- 24 people
- Sponsor
- Climb Bio, Inc.
Immune Thrombocytopenia
Observatory of Immunological Thrombopenic Purpura in the Brest Region
Database of patients with ITP, diagnosed, treated and followed in the Brest University Hospital.
- Trial name
- OPTIMIST (NCT06556888)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Brest
Refractory Immune Cytopenia
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.
- Trial name
- NCT06787989
- Testing
- BCMA-CD19 cCAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Primary Immune Thrombocytopenia (ITP)
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to <18 years of age)…
- Trial name
- VAYHIT-P (NCT07660172)
- Testing
- Ianalumab, Eltrombopag
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Immune Thrombocytopenia
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP).
- Trial name
- NCT07017725
- Testing
- CID-103
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- CASI pharmaceuticals, Inc.
Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP).
- Conditions
- Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
- Trial name
- Advance Jr (NCT07194850)
- Testing
- Efgartigimod IV
- Where
- 26 sites in France, Germany and 8 more
- Volunteers
- 24 people
- Sponsor
- argenx
Primary Immune Thrombocytopenia
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP…
- Trial name
- NCT06900920
- Testing
- TQB3473 Tablets
- Where
- 53 sites in China
- Volunteers
- 199 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
Selective Mediterranean Diet in Immune Thrombocytopenia
This randomized controlled trial aims to evaluate the effect of a selective Mediterranean diet regimen, used as an adjunct to standard therapy, on platelet count and bleeding-related outcomes in adult patients with primary immune…
- Conditions
- Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
- Trial name
- NCT07798050
- Testing
- Selective Mediterranean Diet, Standard Pharmacological Therapy for ITP
- Volunteers
- 60 people
- Sponsor
- Assiut University
Autoimmune Diseases, Lupus Erythematosus, Systemic
Comparative Autoantibody and Immunologic Cell Marker Study
The purpose of this study is to compare immune phenotype, function, and specificity of B lymphocytes from different developmental stages in autoimmune patients to B cells from infectious disease patients and healthy controls.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Trial name
- NCT02422875
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Emory University
Immune Thrombocytopenia, Treatment
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This randomized, open-label study aim to compare the efficacy and safety of rituximab combining anti-CD38 monoclonal antibody with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or…
- Trial name
- NCT07234019
- Testing
- Daratumumab（Anti-CD38 Monoclonal Antibody）, Rituximab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Immune Thrombocytopenic Purpura
Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura
Patients with chronic immune thrombocytopenic purpura (ITP) live with an anxiety-inducing risk of haemorrhage that is unpredictable over several months or years.
- Trial name
- ITP-CPET (NCT07310342)
- Testing
- IPT-CPET
- Where
- 5 sites in France
- Volunteers
- 53 people
- Sponsor
- University Hospital, Bordeaux
Immune Thrombocytopenia (ITP), Acute Ischemic Stroke
Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke
Immune thrombocytopenia (ITP) is an acquired bleeding disorder mediated by immune-related platelet destruction and impaired platelet production.
- Trial name
- NCT07070193
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia (ITP)
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP.
- Trial name
- NCT07095127
- Testing
- NVG-2089
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nuvig Therapeutics, Inc.
Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
The goal of this observational study is to characterize the diagnostic and therapeutic management of autoimmune cytopenias including autoimmune hemolytic anemia, immune thrombocytopenia, and chronic idiopathic/autoimmune…
- Conditions
- Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, Chronic Idiopathic Neutropenia, Autoimmune Neutropenia
- Trial name
- AIHA ITP CIN (NCT05931718)
- Testing
- cytokine essays, NGS, Fecal microbiome
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Immune Thrombocytopenia
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
Background: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder. Corticosteroids are first-line therapy, but about one-third of patients relapse or are refractory.
- Trial name
- NCT07687134
- Testing
- Eltrombopag
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Primary Immune Thrombocytopenia (ITP)
Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy
To evaluate whether orelabrutinib combined with romiplostim N01 can improve the quality of remission, increase the probability of successful drug withdrawal, and prolong the time to treatment failure in patients with primary…
- Trial name
- ORBIT (NCT07400250)
- Testing
- Orelabrutinib, Romiplostim N01
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking Union Medical College Hospital
ITP - Immune Thrombocytopenia
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
This study aims to evaluate the efficacy and safety of Ripertamab in combination with Eltrombopag compared to Eltrombopag alone for patients with Primary Immune Thrombocytopenia (ITP) who have not responded to or have relapsed…
- Trial name
- RPE-ITP (NCT06790888)
- Testing
- Ripertamab/Eltrombopag, Eltrombopag
- Volunteers
- 78 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Immune Thrombocytopenic Purpura ( ITP ), Systemic Lupus Erythematosus (SLE)
Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus
Immunologic thrombocytopenic purpura (ITP) in children is a pre-lupus condition if associated with the presence of anti-nuclear antibodies (ANA), providing a unique model for understanding the natural history of autoimmunity…
- Trial name
- PRELUDE (NCT07680010)
- Testing
- Blood sampling baseline and M3, Monitoring for SLE, Procedure/Surgery: Blood sampling baseline and M3 then each 6 months until 48 months
- Where
- 2 sites in France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Primary Immune Thrombocytopenia (ITP)
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
This prospective, multicenter, randomized study aim to evaluate the efficacy and safety of romiplostim N01 combined with glucocorticoids as the first-line treatment for newly diagnosed adult primary immune thrombocytopenia (ITP).
- Trial name
- NCT06992128
- Testing
- Romiplostim N01 combined with dexamethasone, Dexamethasone monotherapy
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China